htl0016878
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 25, 2017 (NCT03244228)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
CHRM4 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04935320 | Phase 1 | Jul 27, 2021 | Heptares Therapeutics Limited |
| NCT04849286 | Phase 1 | Sep 26, 2018 | Heptares Therapeutics Limited |
| NCT03244228 | Phase 1 | Aug 25, 2017 | Allergan, Heptares Therapeutics Limited |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Heptares Therapeutics Limited | For profit | 3 | 3 | 1 | 2017 |
| Allergan | For profit | 1 | 0 | 1 | 2017 |
2 organizations
Page 1 / 1